Comments
Drugmaker Cipla Ltd has entered into a global licensing agreement (except for East Asia) with MEDRx Company Ltd to develop and commercialise MRX-4TZT, a Tizanidine1 patch for the management of spasticity.
MEDRx is eligible to receive up to $30 million through upfront and developmental, regulatory and commercial milestones payments, a note from Cipla said. MEDRx will also receive tiered royalties on the net sales of commercialised licenced products.
MRX-4TZT is a medicated patch that uses ILTS (Ionic Liquid Transdermal System), an exclusive MEDRx technology to deliver Tizanidine, a centrally acting muscle relaxant.
MEDRx has concluded early stage phase-I trials in the US.
Annual sales of muscle relaxants in the US is pegged at $807 million in 2016. And MRX-4TZT is expected to be the first transdermal muscle relaxant worldwide.
Delivering Tizanidine through the skin rather than orally is expected to improve patient experience with better efficacy and a reduction of adverse events and side effects linked to the drug, the company said.
Cipla plans to initiate late stage or phase-III clinical trials after completion of additional phase-I studies, it added.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.